Novartis Ophthalmics
  Novartis Pharma US

 
CHANGE TEXT SIZE  Decrease Font Size Increase Font Size
Helpful Hints
Help your patients understand how their eyes work, how to care for their eyes, their children's eyes, and what tests they may receive during an eye exam.
Find Out How >

Advancing Excellence in Ophthalmology

Voltaren Ophthalmic® Safety Information



Voltaren Ophthalmic® 
(diclofenac sodium 
ophthalmic solution) 0.1%

In clinical practice, adverse events associated with use of Voltaren Ophthalmic include corneal erosion, corneal infiltrates, corneal perforation, corneal thinning, corneal ulceration, epithelial breakdown, and superficial punctuate keratitis; because these events were reported voluntarily from a population of unknown size, estimates of frequency cannot be made.

Ocular adverse reactions include transient burning and stinging (15% of patients), keratitis (28% of patients after cataract surgery, although keratitis was often noted prior to treatment), elevated intraocular pressure after cataract surgery (15% of patients), and lacrimation (30% of incisional refractive surgery).

Other adverse reactions, occurring in ≤ 5% of patients, include abnormal vision, acute elevated intraocular pressure, blurred vision, conjunctivitis, corneal deposits, corneal edema, corneal opacity, corneal lesions, discharge, eyelid swelling, injection, iritis, irritation, itching, lacrimation disorder, and ocular allergy.

Patients should be instructed to wait at least 5 minutes after using Voltaren Ophthalmic before administering another medication into the eye.

Back to Top

Contraindications and Special Precautions

As with all ocularly applied nonsteroidal anti-inflammatory drugs, Voltaren Ophthalmic should be used with caution in surgical patients with known bleeding tendencies or those receiving medications that may prolong bleeding time.

The anti-inflammatory activity of Voltaren Ophthalmic may mask the onset and/or progression of eye infections. If a patient has an infection or is at risk for one, concomitant antibiotic therapy may be indicated.

Patients should not wear most soft contact lenses while using Voltaren. The one exception is use of a bandage hydrogel soft contact lens during the first 3 days after refractive surgery. Use of hard contact lenses is not recommended.

Voltaren Ophthalmic is contraindicated in patients who are hypersensitive to any component of the medication:

Active ingredient: diclofenac sodium 0.1%.

Inactive ingredients: polyoxyl 35 castor oil, boric acid, tromethamine, sorbic acid (2 mg/mL), edetate disodium (1 mg/mL), and purified water.

Full Prescribing Information

Back to Top


Voltaren Ophthalmic® 
(diclofenac sodium 
ophthalmic solution) 0.1%

Voltaren Ophthalmic® Safety Information
EYE DISEASES & DISORDERS
Facts on specific eye diseases
Read More >



Home  |  Professional Main Page  |  About Ophthalmics  |  Products
Eye Diseases & Disorders  |  Patient Education Library
Patient Assistance Program  |  Press Releases

Contact Us  |  Site Guide  |  Site Map

Novartis Pharma US Use of website is governed by the Terms of Use and Privacy Statement .
Copyright ©2007
Novartis Pharmaceuticals Corporation. All rights reserved.